Age-related Macular Degeneration (AMD)

The “macula” describes the area at the very center of the retina. It has a diameter of approximately 5mm, and it is the site of sharpest vision. Without a functioning macula, it is difficult or impossible to focus on objects, read, recognize faces or watch TV.

With advancing years, dry macular degeneration leads to a buildup of metabolic waste products under the retina. In turn, this leads to the disintegration of retinal tissue. At the moment, there is no established treatment method for age-related dry macular degeneration. However, it is important for dry AMD patients to undergo regular check-ups because dry AMD can turn into a wet AMD.

As wet macular degeneration progresses, new damaged blood vessels appear under the retina. This leads to leakage and bleeding under and in the retina, as well as severe swelling in the macula. Both forms of AMD lead to a severe impairment of visual acuity. However, the deterioration is a lot faster in the case of the wet AMD form. Wet AMD is treated with the Lucentis / Eylea preparations, which have been around since 2006. Using a fine needle, the drug is injected into the intraocular space (vitreous) in order to improve and stabilize visual acuity.

The injections have to be carried out in an operating room. We are capable of conducting all the necessary check-ups, assessments and treatment in our clinic on the Casinoplatz. This results in a significant simplification of the procedure, saving time for patients and their escorts.